Comprehensive proteomic and pathological profiling identifies PRAS40 as a novel biomarker and mediator of primary immune checkpoint blockade resistance in non-small cell lung cancer
PRAS40 is strongly associated with primary ICB resistance in NSCLC and may serve as a novel predictive biomarker. These findings support its potential to guide personalized immunotherapy in lung cancer.
Authors
- Jia Kuang
- Ning Mao (ORCID: https://orcid.org/0000-0001-5437-3548)
- Cui He (ORCID: https://orcid.org/0000-0001-7050-4915)
- Zhao Yang (ORCID: https://orcid.org/0000-0002-9626-9359)
- Chunguang Wang
Institutions
- Dalian Medical University (CN)
- Second Affiliated Hospital of Chongqing Medical University (CN)
- Chongqing Medical University (CN)
Publication Details
- Journal
- Cancer Immunology Immunotherapy
- Published
- 2025-10-10
- DOI
- https://doi.org/10.1007/s00262-025-04166-1
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Chongqing Medical University